Last reviewed · How we verify
Placebo for Pancrease MT 10.5 or MT 21 — Competitive Intelligence Brief
phase 3
Gastrointestinal
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo for Pancrease MT 10.5 or MT 21 (Placebo for Pancrease MT 10.5 or MT 21) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. This is a placebo, meaning it has no active therapeutic effect.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo for Pancrease MT 10.5 or MT 21 TARGET | Placebo for Pancrease MT 10.5 or MT 21 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo for Pancrease MT 10.5 or MT 21 CI watch — RSS
- Placebo for Pancrease MT 10.5 or MT 21 CI watch — Atom
- Placebo for Pancrease MT 10.5 or MT 21 CI watch — JSON
- Placebo for Pancrease MT 10.5 or MT 21 alone — RSS
Cite this brief
Drug Landscape (2026). Placebo for Pancrease MT 10.5 or MT 21 — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-for-pancrease-mt-10-5-or-mt-21. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab